9 patents
Utility
Method of controlling depression in subjects treated for opioid dependence
4 Apr 23
The present disclosure is directed to a method of combatting opioid dependence in a subject experiencing a depressive episode.
Michael John Sumner
Filed: 30 Jun 21
Utility
Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
6 Sep 22
There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.
Andreas Fischer
Filed: 25 Sep 20
Utility
Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
1 Jun 21
There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.
Andreas Fischer
Filed: 25 Sep 20
Utility
Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
1 Jun 21
There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.
Andreas Fischer
Filed: 25 Sep 20
Utility
Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
16 Mar 21
There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.
Andreas Fischer
Filed: 1 Sep 20
Utility
Pharmaceutical composition for nasal delivery
26 Jan 21
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier.
Jonas Sävmarker, Robert Rönn
Filed: 27 Jul 20
Utility
Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
28 Dec 20
There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.
Andreas Fischer
Filed: 30 Jul 18
Utility
Pharmaceutical composition for nasal delivery
3 Aug 20
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier.
Jonas Sävmarker, Robert Rönn, Andreas Fischer
Filed: 17 May 20
Utility
Pharmaceutical composition for nasal delivery
18 May 20
There is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist.
Jonas Sävmarker, Robert Rönn, Andreas Fischer
Filed: 8 Jul 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first